WDFY2 Inhibitors
The class of chemicals known as WDFY2 inhibitors encompasses a diverse set of compounds that intricately modulate cellular pathways to hinder WDFY2 activity. One prominent inhibitor within this class is Wortmannin, which disrupts WDFY2 by inhibiting phosphatidylinositol 3-kinase (PI3-kinase). This inhibition reduces the recruitment of WDFY2 to endosomal membranes, impairing its role in autophagy and endocytosis. Wortmannin's specific targeting of PI3-kinase highlights the precision with which these inhibitors operate to modulate cellular processes, providing a focused approach to hindering WDFY2 activity.
Another notable WDFY2 inhibitor is Spautin-1, which employs a unique mechanism to compromise WDFY2 function. Spautin-1 inhibits ubiquitin-specific peptidases, USP10 and USP13, leading to the degradation of Beclin1. Beclin1 is an essential component in autophagy-related processes, and its degradation indirectly inhibits WDFY2. This indirect inhibition showcases the interconnected nature of cellular pathways and the strategic approach taken by inhibitors to disrupt WDFY2 activity. Spautin-1's mechanism provides valuable insights into the regulation of WDFY2 and its involvement in crucial cellular processes. Collectively, these WDFY2 inhibitors, including Wortmannin and Spautin-1, offer insights into the regulation of WDFY2 activity and its role in essential cellular processes. The precise modulation of cellular pathways, such as PI3-kinase inhibition by Wortmannin and Beclin1 degradation by Spautin-1, highlights the sophistication of these inhibitors in compromising WDFY2 function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3-kinase, disrupting the PI3K/Akt signaling pathway. The altered signaling cascade indirectly inhibits WDFY2 by reducing its recruitment to endosomal membranes, impairing its function in autophagy and endocytosis. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 inhibits USP10 and USP13, promoting the degradation of Beclin1. The decreased levels of Beclin1 disrupt autophagy and indirectly inhibit WDFY2 by preventing its interaction with autophagic vesicles, impairing its role in autophagy-related processes. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine inhibits PI3-kinase class III, affecting autophagosome formation. The disrupted autophagy indirectly inhibits WDFY2 by impeding its recruitment to autophagic vesicles, compromising its function in autophagy-related processes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 inhibits vacuolar H+-ATPase, affecting lysosomal acidification. The altered lysosomal pH disrupts autophagy and indirectly inhibits WDFY2 by impairing its fusion with autophagic vesicles, compromising its function in autophagy-related processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 inhibits p38 MAPK, disrupting the p38 MAPK signaling pathway. The modified signaling cascade indirectly inhibits WDFY2 by affecting its recruitment to endosomal membranes, impairing its role in endocytosis and vesicle trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3-kinase, disrupting the PI3K/Akt signaling pathway. The altered signaling cascade indirectly inhibits WDFY2 by reducing its recruitment to endosomal membranes, impairing its function in endocytosis and vesicle trafficking. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine inhibits lysosomal function, affecting autophagy. The disrupted autophagy indirectly inhibits WDFY2 by impeding its fusion with autophagic vesicles, compromising its function in autophagy-related processes. | ||||||
SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
SAR-405 inhibits PI3-kinase class III, affecting autophagosome formation. The disrupted autophagy indirectly inhibits WDFY2 by impeding its recruitment to autophagic vesicles, compromising its function in autophagy-related processes. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64d is a cysteine protease inhibitor, affecting lysosomal function. The altered lysosomal activity disrupts autophagy and indirectly inhibits WDFY2 by impeding its fusion with autophagic vesicles, compromising its function in autophagy-related processes. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB 202190 inhibits p38 MAPK, disrupting the p38 MAPK signaling pathway. The modified signaling cascade indirectly inhibits WDFY2 by affecting its recruitment to endosomal membranes, impairing its role in endocytosis and vesicle trafficking. | ||||||